The most crucial factor in accurately diagnosing, prognosticating and treating complex human diseases such as cancer, autoimmune diseases and neurodegenerative disorders is often referred to as biomarkers. Biomarkers are important biological molecules that serve as an indicator of our health and can be used to aid in clinical decisions. Unfortunately, identifying a novel and robust protein biomarker has typically been a slow and challenging process using traditional methods with a lack of throughput and sensitivity. Creative Biolabs stands at the forefront of phage display technology to build an efficient high-throughput platform for discovering new biomarkers. Our advanced services for finding the next generation of biomarkers for all types of diseases will help you identify the disease-specific biomarkers and push your lab discoveries forward faster. Supported by our extensive phage display services, Creative Biolabs is confident it will be the best phage display partner for biomarker discovery for your research.
Fig.1 Creative Biolabs' workflow for phage display biomarker discovery.
Precision medicine is an ever-growing field across the globe. Consequently, biomarker discovery is a common endpoint to almost all biomedical research endeavours. Biomarkers reveal molecular details about biological processes while finding use in disease diagnosis, prognosis, and therapeutic prediction alongside patient stratification. Implementing liquid-based diagnostic methods with minimal invasiveness and patient-specific analysis has urgently required biomarkers that demonstrate exceptional sensitivity and specificity.
Phage display is one of the most flexible and robust platforms to meet this need. Phage display is a technology developed in the 1980s that allows a peptide, antibody fragment or protein to be displayed on the surface of a bacteriophage virus particle. Libraries of these phages can then be screened against virtually any target, from purified proteins and cell surface markers to complex biological matrices like serum or CSF, using biopanning. Phage display screening operates without bias and does not rely on existing knowledge of the disease target being investigated. Clinical samples enable researchers to discover new binders de novo through high-throughput methods. Coupled with next-generation sequencing (NGS), a systems-level view of the antibody or peptide can be obtained. These technologies can discover diagnostic biomarkers, autoantibody biomarkers, prognostic biomarkers, and even therapeutic antibody leads.
Creative Biolabs offers cutting-edge phage display services for biomarker discovery, allowing researchers to screen for diagnostic biomarkers, prognostic biomarkers, and therapeutic targets with high precision. Whether you are searching for cancer biomarkers, autoantibody targets, or neurodegenerative disease biomarkers, our services provide comprehensive solutions to meet your specific research needs.
In cancer research, identifying tumor-associated biomarkers is crucial for developing diagnostic assays and therapies. Our phage display platform enables the identification of tumor-specific antigens (TSAs) and circulating tumor-specific autoantibodies using phage display antibody discovery. This technology has significant potential for liquid biopsy applications, allowing non-invasive cancer detection through serum biomarkers. We utilize scFv libraries and peptide libraries to identify high-affinity binders to cancer antigens, improving early detection and facilitating targeted therapies.
Phage Display Cancer Biomarker Screening →
For neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and ALS, early diagnosis is essential for effective treatment. Cerebrospinal fluid (CSF), being in direct contact with the central nervous system, contains valuable biomarkers that reflect neuronal damage and inflammation. Using our phage display biopanning protocols, we identify CSF biomarkers that indicate disease progression or predict treatment outcomes. This approach offers critical insights for neurodegenerative disease diagnosis and therapeutic monitoring.
Phage Display CSF Neuro Biomarkers →
Phage display is an ideal tool for identifying pathogen-specific biomarkers and host-response markers in infectious diseases. Whether bacterial, viral, or parasitic infections, our peptide libraries can help uncover pathogen-derived antigens or host antibodies. This allows for the development of new diagnostic tools and vaccines. We specialize in phage display screening of host immune responses or pathogen antigens, enabling researchers to identify biomarkers for early disease detection, vaccine development, and monitoring of infectious disease progression.
Phage Display Infectious Disease Biomarkers →
Cardiovascular diseases, such as atherosclerosis, myocardial infarction, and heart failure, are leading causes of morbidity and mortality worldwide. Early diagnosis through cardiovascular biomarkers can help identify at-risk individuals, monitor disease progression, and guide therapeutic interventions. Our phage display platform helps uncover circulating protein biomarkers associated with vascular inflammation, lipid metabolism, and cardiac injury, providing insights for diagnostic and therapeutic applications in cardiovascular health.
Phage Display Cardiovascular Protein Markers →
In autoimmune diseases like lupus, rheumatoid arthritis, and multiple sclerosis, the presence of autoantibodies is a key feature. Using phage display antibody discovery, we identify autoantibody biomarkers that can be used for diagnostic purposes and to understand disease mechanisms better. Our phage display screening services allow us to isolate autoantibodies from patient sera, enabling early diagnosis and monitoring of autoimmune diseases.
Phage Display Autoimmune Disease Autoantibody Discovery →
Our phage display method involves a streamlined workflow that ensures high-quality results with reproducible outcomes. The process is designed to optimize the selection of high-affinity binders from large libraries, and it can be customized to accommodate the specific needs of each research project.
Creative Biolabs offers an array of customizable phage display platforms that can be used for diverse applications across various diseases. Our platforms are optimized for high-throughput screening and provide unparalleled sensitivity in identifying high-affinity binders.
| Platform Type | Description |
|---|---|
| Antibody Phage Display | It is used for scFv antibody discovery, therapeutic antibody discovery, and autoantibody biomarker identification. |
| Peptide Phage Display | Ideal for screening epitope-specific peptides and identifying protein biomarkers for pathogen detection |
| Mirror-Image Display | For the identification of stable D-peptides with therapeutic potential |
| T7/λ/Filamentous M13 | Employs filamentous phage systems for efficient phage display applications |
| NGS-Enabled Phage Display | Combines phage display screening with NGS to obtain highly accurate binding profiles |
At Creative Biolabs, we pride ourselves on our extensive experience and commitment to delivering high-quality phage display services. We have years of expertise in biomarker discovery, antibody development, and therapeutic antibody identification, making us the trusted partner for your biomarker research needs. We offer a comprehensive, end-to-end solution, from library construction to target validation and biomarker identification, ensuring you receive actionable insights for your research projects.
The search for novel biomarkers is a race against time. With Creative Biolabs' advanced phage display platform, you can significantly accelerate your research and increase your chances of success. Our comprehensive technology, deep expertise, and collaborative approach provide the power and precision needed to uncover the next generation of diagnostic and prognostic tools. Don't let your valuable samples go unexplored. Ready to unlock the biomarker potential in your samples? to discuss your project and learn how our phage display services can help you achieve your research goals.
The power of combining phage display with advanced computational analysis is not just theoretical. A landmark study exemplifies the success of this integrated approach for discovering highly specific T-cell receptors (TCRs), which function similarly to antibody binders in diagnostics and therapy. In this research, scientists constructed a vast phage display library based on a TCR that targets the clinically significant cancer antigen NY-ESO-1. By panning this library against the target, they generated a massive dataset of thousands of unique, antigen-specific TCR sequences. This wealth of data was then used to train a specialized machine learning model designed to predict TCR-epitope interactions. The model demonstrated remarkable predictive power. When applied to screen vast, native TCR repertoires, it successfully identified novel TCR candidates that were previously unknown. Subsequent cellular assays confirmed that these newly discovered TCRs were functionally active against the NY-ESO-1 cancer antigen. Crucially, unlike many artificially affinity-enhanced TCRs, these naturally-derived binders showed no detectable off-target cross-reactivity. This work powerfully validates our strategy: using high-throughput phage display to generate large-scale data can fuel machine learning models to rapidly discover potent and highly specific biomarkers directly from natural biological diversity.
Fig.2 Experimental workflow of phage display for identifying cancer antigen-specific TCRs.1
Q: What types of samples can be used for biomarker discovery?
A: A wide variety of biological samples can be used, including serum, plasma, cerebrospinal fluid, urine, saliva, tissue homogenates, and cell lysates. The best sample type depends on the disease and the specific research question.
Q: How is NGS superior to traditional methods in phage display?
A: Next-generation sequencing (NGS) allows for the simultaneous sequencing of millions of DNA fragments. In phage display, we can get a deep, quantitative profile of the entire enriched phage population after biopanning, identifying not just the most abundant binders but rarer candidates that would be missed by traditional, low-throughput Sanger sequencing.
Q: Can you help if I already have a binder and must identify its target?
A: Yes. We offer standalone target identification services. Suppose you have an antibody, peptide, or other molecule and must identify its binding partner in a complex biological sample. In that case, we can use it as a "bait" to pull down and identify the target protein using mass spectrometry.
Q: Do you offer a phage display kit?
A: While we are primarily a service provider, we offer custom-built libraries for clients with specific needs. Leverages our optimized protocols and expert analysis for the most efficient and reliable results.
Reference:
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
